NJ3b

NJ3b is a synthetic phenothiazine derivative designed as a dual-target inhibitor for the treatment of Alzheimer's disease. It functions by simultaneously inhibiting Monoamine Oxidase B (MAO-B) and Acetylcholinesterase (AChE). By targeting MAO-B, NJ3b aims to mitigate oxidative stress, neuroinflammation, and protein aggregation, while its inhibition of AChE addresses the cholinergic deficit and neurotransmission impairment characteristic of the disease. Developed by researchers at the JSS Academy of Higher Education and Research, NJ3b has demonstrated high binding affinity in molecular docking studies and low cytotoxicity in vitro. However, initial evaluations indicate mediocre blood-brain barrier (BBB) permeability, suggesting that further development may require nanoformulation strategies to enhance CNS delivery and efficacy.